PE-22-28NootropicSafety Rating 6/10
Primary research areaDepression
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose rangeResearch compound. Animal studies: 0.5–1 mg/kg SC. Human dosing protocols emerging.
AdministrationVaries
Safety6/10 · Not FDA-approved
NCAA D1Not listed
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| PeptiraBest $/mgCOA ✓ · 3P | $49.00 | $4.90 | May 14, 2026 | Buy → |
| Modern AminosCOA ✓ · 3P | $58.00 | $5.80 | May 14, 2026 | Buy → |
| SomaChemsCOA ✓ · 3P | $59.99 | $6.00 | May 14, 2026 | Buy → |
| Core PeptidesCOA ✓ · 3P | $54.00 | $6.75 | Apr 16, 2026 | Buy → |
| PureRawzCOA ✓ · 3P | $65.02 | $8.13 | May 14, 2026 | Buy → |
Overview
About PE-22-28
Mechanism of action
Optimized analogue of spadin; selective TREK-1 (K2P potassium channel) blocker; activates serotonergic neurotransmission; antidepressant effects via BDNF upregulation; fast-acting.
Safety profile
Very limited human data. Well-tolerated in animal studies. Theoretical serotonergic side effects. · Spadin analog; TREK-1 inhibitor; animal data favorable; no proven harms; early stage
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops PE-22-28 below your target.
Related pages